Navigation

Investiment.io
Financial analysis platform

Bristol-Myers Squibb Company

BMY • NYSE

$63.33
▼0.10 (0.16%)• REGULAR

Bristol-Myers Squibb Company

$63.33
▼0.2%
📊Summary📋SEC Filings👥Insider Trading
📄

BMY Q1 2024 Earnings Call

April 25, 2024 at 12:00 AM

Company
BMY
Quarter
Q1 2024
Date
April 25, 2024 at 12:00 AM
Speakers
2
Word Count
~2,444

Transcript Content

Speaker
Just had one for Chris or maybe for David. On the cost savings, how much would you say was legacy Bristol, either workforce or facilities versus optimizing integration of all your recent deals? I guess I'm trying to get a sense for whether you think there's further optimization to come as you guys focus on the new launch portfolio. David Elkins (CFO): Yes. Thanks, Jeff, for the question. The majority of the savings come from the historical BMS. As we talked about, the main drivers of the $1.5 billion savings really came into three buckets. First was really looking at the portfolio, obviously, with the Mirati, Karuna, and RayzeBio, we have really important portfolios that we're bringing into the overall portfolio. That gave us the opportunity to look at that and maximize the ROI of the totality of the portfolio as well as adjusting for some updates on new data and the competitiveness. The second thing that we really looked at for legacy BMS is how do we become more agile, quicker decision-making, and streamline the organization by removing layers of management so decisions can be made more quickly. And there, we talked about the roughly 2,200 impacted employees as a result of those changes. And then lastly, we went through all of our third-party relationships, continuing to look for efficiencies in third-party service providers, and that was the last category. And a lot of those activities are also legacy BMS. So the vast majority of the savings are coming from our in-house existing operations. Christopher Boerner (CEO): Thanks, Chris. Let me just say a couple of words and then I'll turn it over to David for the first part of your question, then Adam can come in on the back end. First, as David mentioned, when we thought about these efficiencies, we were really thinking along three lines: the need to invest in the pipeline; ensuring that we had adequate investment for our growth products; and then needing to be more agile and focused as an organization. In terms of how we think about allocating those redeployment opportunities, I would say, generally speaking, they're in that order with the majority going back into R&D. David Elkins (CFO): Thank you for your question, Chris. To clarify, roughly two-thirds of the savings are attributed to R&D, while about one-third comes from MS&A. It’s also important to consider our recent acquisitions, particularly Mirati and Krazati, which are crucial for our development programs in first-line lung cancer, covering both the doublet and triplet therapies. Additionally, with Karuna, there are several significant opportunities in this area. We previously discussed schizophrenia and are also expanding into Alzheimer’s, particularly with agitation and psychosis. Therefore, these areas require substantial investments.
Speaker
Thank you, David. Building on what he mentioned, we took a careful approach to evaluate our pipeline and identify assets we would not pursue further. We analyzed the evolving science behind our clinical assets. For instance, regarding our development of CTLA-4, we established a high benchmark with ipilimumab. Upon reviewing the data, we determined that if it wasn't going to outperform ipilimumab, there was no reason to continue the program, so we chose not to proceed with it. Similarly, our assessment of the SIRP alpha program, based on both external and internal data, indicated that it did not meet our standards. We also considered the potential return on investment for patients and decided not to carry on with that program. Additionally, we evaluated whether a program, despite having strong scientific data, would make sense for our company’s size and growth goals. In the case of BET 158, while the data in myelofibrosis may be promising, it does not meet our criteria for being a significant driver of growth, so we will not continue with that program.
Speaker
Yes. Chris, thanks for the question. So we're making good progress across the totality of our growth portfolio. As David shared, we saw strong year-on-year demand growth across the majority of our growth products. And we continue to be focused on accelerating our key brands. And we're doing what we said we would do as we continue to drive our growth portfolio. So just a few of the products that I think is important to mention. Opdualag has become a new standard of care in first-line metastatic melanoma, grew 76%. Reblozyl continues to deliver strong performance post-first-line. COMMANDS approval grew over 70% as well. We have increased investment at the end of last year behind products like SOTYKTU, Breyanzi, and Camzyos. Camzyos continues to demonstrate strong growth. We had 25% growth of new patients added onto commercial drugs quarter-over-quarter. Breyanzi, we also increased our investment. We're in a much stronger supply position today than we were last year and increasingly being recognized as a best-in-class CAR-T. And as David mentioned, we're readying for the launch of KarXT in September, which is a very significant multibillion-dollar opportunity. Timothy Power (Head of Investor Relations): Thanks, David. Can we go to the first question, please?
Operator
Our first question comes from Geoff Meacham with Bank of America. Christopher Boerner (CEO): Yes. Thanks for the question, Seamus. Maybe I'll start, have Adam weigh in a little bit more on IRA. With respect to the ongoing discussions with CMS, we're not going to be commenting. As I said earlier, we will have the outcome of that public in September and we'll be able to provide more insight at that point. But Adam, you can speak to some of the other aspects of IRA and then Samit.
Speaker
Thank you, Chris and Seamus, for the question. Regarding the IRA, there are several components to consider, including negotiations and changes to the Part D benefit design. For 2024, we do not expect a significant impact across our portfolio, including Eliquis, Revlimid, and other brands. However, we anticipate more substantial changes to the Part D benefit next year due to the redesign affecting these products. We are currently evaluating the individual dynamics of each product and will monitor the situation closely to gauge the impact of new measures, such as out-of-pocket caps and other system changes. For instance, as we move from a $3,500 cap to a $2,000 cap, we expect more patients to fill their prescriptions successfully as costs at the pharmacy decrease. Nonetheless, we will need more data before providing additional details.
Speaker
Thank you, Adam. And then thanks, Seamus, for the question. For Opdualag, let's just take a step back and understand what we were planning to do and try to do. So for Opdualag, we conducted a study of Opdualag plus chemotherapy in first-line non-small cell lung cancer. At first, we wanted to define the dose. So we tested a couple of doses in the first part of the study. And in the second part of the study, we then randomized the patient to receive Opdualag plus chemotherapy versus nivolumab plus chemotherapy. And as we have said before, what we wanted to understand, is the drug applicable for all patients? Or are we going to find a differential activity in a subset of patients? And what we have said is we have found a subgroup of patients where the drug's activity is good and encourages us to now go into a Phase III trial. And so we are looking forward to presenting the data in the second half of this year as well as initiating the trial versus standard of care in the second half of this year. Timothy Power (Head of Investor Relations): Thanks, Adam. We're starting to run a little short on time, maybe take 2 or 3 more. Can we go to the next one?
Operator
Our next question comes from James Shin with Deutsche Bank.
Speaker
Certainly, I can take that question. Look, obviously, I can't comment on what others have seen. All we know is they've seen six patients worth of data. Hard to compare six patients worth of data with more than 200 patients treated with Opdualag plus chemotherapy in the first-line setting. What we have seen is overall review of our own data set, looking at the various endpoints that we looked at as well as the biomarkers we looked at in our profile and we remain confident in the profile of the drug to take it forward into the Phase III. Christopher Boerner (CEO): Well, let me start and then I'll ask Samit and Adam to speak. Let me just at a high level, though, say that we continue to be incredibly excited about radiopharmaceuticals as a platform. It's one of the fastest-growing platform in solid tumor oncology. We believe we have a best-in-class asset that we've acquired with Rayze. The integration of that team has gone very well. We continue to be very excited and happy with the bringing online of the facility in Indianapolis. So in terms of us getting that asset, incredible enthusiasm and the integration has gone well. But Samit, maybe you and Adam can speak to details.
Speaker
I will add a few points. RayzeBio was a significant strategic acquisition that we believe helps diversify our oncology portfolio. As Chris mentioned, we expect this modality to continue growing over time. It will be competitive, but what we find appealing about RayzeBio is its potential as an IND engine. The lead program, RYZ101, is already in Phase III development for GEP-NET, as mentioned earlier. We also see opportunities in small cell lung cancer, breast cancer, and potentially other tumor types. This acquisition is highly complementary to our existing portfolio. Timothy Power (Head of Investor Relations): And maybe we could go to our last question, if you don't mind, Rocco?
Operator
Our final question comes from Akash Tewari with Jefferies.